Tysabri and PML: What Washington Patients Should Know About the Timeline

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Specific Legal Concerns

If you or a family member took Tysabri and are now facing a PML diagnosis, understanding the timeline of exposure and symptom onset is critical. For decades, medical literature has documented the link between Tysabri and progressive multifocal leukoencephalopathy, shaping how clinicians and patients approach risk. This page outlines the key facts about Tysabri PML history, including what Washington records show about short- and long-term use.

Understanding Tysabri and Its Link to PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis in adults (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic viral infection of the brain caused by the John Cunningham virus (JCV). The U.S. Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri, stating that the drug increases the risk of PML, which usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is based on clinical evidence and postmarketing surveillance data. The clinical presentation of PML is characterized by progressive neurological deficits, including cognitive impairment, motor dysfunction, visual disturbances, and speech difficulties. Diagnosis typically involves brain imaging, such as MRI, and detection of JCV DNA in cerebrospinal fluid via polymerase chain reaction (PCR). The disease can develop insidiously, with symptoms often mistaken for multiple sclerosis relapses, delaying recognition and treatment. The FDA Adverse Event Reporting System (FAERS) database lists fatigue, multiple sclerosis relapse, headache, gait disturbance, and memory impairment among the most frequently reported adverse events associated with Tysabri (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not directly confirm PML, they highlight the range of neurological symptoms that may overlap with early PML signs.

Mechanistic Pathways and Risk Factors for PML

Mechanistic pathways linking Tysabri to PML involve the drug's action as an alpha-4 integrin antagonist. Tysabri blocks the adhesion of immune cells to endothelial surfaces, preventing their migration across the blood-brain barrier. This reduces inflammatory activity in the central nervous system, which is beneficial for multiple sclerosis but also impairs immune surveillance against JCV. Under normal conditions, JCV is controlled by the immune system, but with reduced T-cell trafficking to the brain, the virus can reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and PML. Risk factors for PML include the presence of anti-JCV antibodies, longer duration of Tysabri therapy, and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when assessing the benefit-risk profile for each patient. The adequacy of warnings regarding Tysabri and PML is a critical issue. The FDA requires a boxed warning, and Tysabri is only available through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients must be enrolled, read the Medication Guide, understand the risks, and sign a Patient Enrollment Form. Healthcare professionals are instructed to monitor patients for any new signs or symptoms suggestive of PML and to withhold Tysabri immediately if such symptoms appear (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, questions may arise about whether patients and providers were adequately informed about the specific risk of PML, especially in cases where symptoms were not promptly recognized or where the drug was continued despite known risk factors.

Legal Considerations for Washington Residents

For affected patients in Washington, attorney-related considerations involve the statute of limitations for filing a product liability or medical malpractice claim. In Washington, the statute of limitations for personal injury claims is generally three years from the date the injury was discovered or should have been discovered. For claims involving Tysabri and PML, the timeline between exposure and documented harm is crucial. PML can develop months to years after starting Tysabri, and symptoms may be subtle initially. The duration of treatment prior to onset can range from a few months to several years, as noted in postmarketing reports of herpes infections (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This latency complicates the determination of when the injury was discovered. Patients who develop PML may face severe disability or death, and their families may need to act promptly to preserve legal rights. Consulting with an attorney experienced in pharmaceutical litigation is advisable to assess individual circumstances and ensure compliance with Washington's filing deadlines. In summary, Tysabri is associated with a significant risk of PML, as reflected in FDA boxed warnings and postmarketing data. The mechanistic link involves impaired immune surveillance due to the drug's action on integrin receptors. While warnings exist through the TOUCH program, questions about their adequacy may arise in individual cases. For Washington residents affected by Tysabri-related PML, understanding the statute of limitations and the timeline of exposure and harm is essential for pursuing legal recourse.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Washington?

In Washington, the statute of limitations for personal injury claims is generally three years from the date the injury was discovered or should have been discovered. For Tysabri-related PML, this means the clock starts when the patient or their family becomes aware of the link between the drug and the injury. Due to the latency of PML, it is crucial to consult an attorney promptly to avoid missing the deadline.

What are the risk factors for developing PML while on Tysabri?

Risk factors include the presence of anti-JCV antibodies, longer duration of Tysabri therapy (especially beyond two years), and prior use of immunosuppressants. These factors are outlined in the FDA boxed warning and the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.